dexamethasone,lenalidomide,carfilzomib,daratumumab
amgen,janssen
['ascent', 'mmsm']
#ash22 #mmsm interesting observation-ascent median f/u: 25.8 (95% ci, 21.3-29.1) months 38 patients (44%) remain on treatment forty-one (47%) patients have completed all 24 cycles only 44% remains on ttt thoughts ?
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities